The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMRN | +69.68% | -80.31% | -27.75% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +1,388% |
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
There was unambigously good news about the company's single commercialized medication.
The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $73.60M | 8.9% |
| Gross Profit | $50.22M | 19.4% |
| Gross Margin | 68.23% | 6.0% |
| Market Cap | $336.05M | 18.9% |
| Market Cap / Employee | $1.22M | 0.0% |
| Employees | 275 | 0.0% |
| Net Income | -$14.31M | -1038.9% |
| EBITDA | $7.59M | 3099.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $148.18M | -31.5% |
| Accounts Receivable | $119.13M | -3.7% |
| Inventory | 171.2 | -28.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.34M | -9.4% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.10% | -10.1% |
| Return On Invested Capital | -9.28% | -2.6% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.24M | -1932.6% |
| Operating Free Cash Flow | $16.69M | 704.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.49 | 0.41 | 0.39 | 0.71 | 37.06% |
| Price to Sales | 1.06 | 0.87 | 0.86 | 1.53 | 42.94% |
| Price to Tangible Book Value | 10.03 | 7.76 | 7.85 | 0.73 | -93.15% |
| Enterprise Value to EBITDA | 1.63 | 1.70 | 5.53 | 5.86 | -108.66% |
| Return on Equity | -7.3% | -15.8% | -17.2% | -20.4% | 241.49% |
| Total Debt | $8.22M | $7.72M | $7.94M | $7.34M | -9.40% |
AMRN earnings call for the period ending December 31, 2024.
AMRN earnings call for the period ending September 30, 2024.
AMRN earnings call for the period ending June 30, 2024.
AMRN earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
